Suppr超能文献

年龄与急性冠状动脉综合征患者接受治疗和结局之间的关系:心肌缺血国家审计项目(MINAP)的队列研究。

The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP).

机构信息

Department of Emergency Medicine,James Paget University Hospital, Lowestoft Road, Gorleston-on-Sea, Norfolk NR31 6LA, UK Department of Medicine, University of East Anglia, Norwich, UK

Department of Medicine, University of East Anglia, Norwich, UK.

出版信息

Eur Heart J. 2014 Jun 14;35(23):1551-8. doi: 10.1093/eurheartj/ehu039. Epub 2014 Mar 18.

Abstract

AIMS

Older people increasingly constitute a large proportion of the acute coronary syndrome (ACS) population. We examined the relationship of age with receipt of more intensive management and secondary prevention medicine. Then, the comparative association of intensive management (reperfusion/angiography) over a conservative strategy on time to death was investigated by age.

METHODS AND RESULTS

Using data from 155 818 patients in the national registry for ACS in England and Wales [the Myocardial Ischaemia National Audit Project (MINAP)], we found that older patients were incrementally less likely to receive secondary prevention medicines and intensive management for both ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). In STEMI patients ≥85 years, 55% received reperfusion compared with 84% in those aged 18 to <65 [odds ratio 0.22 (95% CI 0.21, 0.24)]. Not receiving intensive management was associated with worse survival [mean follow-up 2.29 years (SD 1.42)] in all age groups (adjusted for sex, cardiovascular risk factors, co-morbidities, healthcare factors, and case severity), but there was an incremental reduction in survival benefit from intensive management with increasing age. In STEMI patients aged 18-64, 65-74, 75-84, and ≥85, adjusted hazard ratios (HRs) for all-cause mortality comparing conservative treatment to intensive management were 1.98 (1.78, 2.19), 1.65 (1.51, 1.80), 1.62 (1.52, 1.72), and 1.36 (1.27, 1.47), respectively. In NSTEMI patients, the respective HRs were 4.37 (4.00, 4.78), 3.76 (3.54, 3.99), 2.79 (2.67, 2.91), and 1.90 (1.77, 2.04).

CONCLUSION

We found an incremental reduction in the use of evidence-based therapies with increasing age using a national ACS registry cohort. While survival benefit from more intensive management reduced with older age, better survival was associated with intensive management at all ages highlighting the requirement to improve standard of care in older patients with ACS.

摘要

目的

老年人在急性冠状动脉综合征(ACS)患者中所占比例越来越大。我们研究了年龄与更强化的管理和二级预防药物治疗之间的关系。然后,我们根据年龄研究了强化治疗(再灌注/血管造影)与保守治疗策略相比对死亡时间的比较关联。

方法和结果

利用来自英格兰和威尔士国家 ACS 登记处(Myocardial Ischaemia National Audit Project,MINAP)的 155818 例患者的数据,我们发现,对于 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型心肌梗死(NSTEMI)患者,年龄较大的患者越来越不可能接受二级预防药物和强化管理。在年龄≥85 岁的 STEMI 患者中,有 55%接受了再灌注治疗,而年龄在 18 至<65 岁的患者中有 84%接受了再灌注治疗[比值比 0.22(95%CI 0.21,0.24)]。在所有年龄段(调整性别、心血管危险因素、合并症、医疗保健因素和病例严重程度)中,未接受强化管理与生存预后较差相关(平均随访 2.29 年[SD 1.42]),但随着年龄的增长,强化管理的生存获益呈递减趋势。在年龄为 18-64 岁、65-74 岁、75-84 岁和≥85 岁的 STEMI 患者中,与保守治疗相比,比较全因死亡率的调整危险比(HR)分别为 1.98(1.78,2.19)、1.65(1.51,1.80)、1.62(1.52,1.72)和 1.36(1.27,1.47)。在 NSTEMI 患者中,相应的 HR 分别为 4.37(4.00,4.78)、3.76(3.54,3.99)、2.79(2.67,2.91)和 1.90(1.77,2.04)。

结论

我们发现,随着 ACS 国家登记队列年龄的增加,使用基于证据的治疗方法的比例呈递减趋势。尽管随着年龄的增长,强化治疗的生存获益减少,但在所有年龄段,强化治疗都与更好的生存相关,这突出表明需要改善 ACS 老年患者的标准治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验